Learn about semaglutide’s effectiveness and clinical trial results and whether it could be right for you in your MASH ...

Semaglutide can help the body make more insulin and improves insulin sensitivity, which in turn lowers blood-glucose levels ...

The MarketWatch News Department was not involved in the creation of this content.-- Wegovy(R) (semaglutide injection) granted conditional marketing authorization for the treatment ...

Results of part 1 of the ESSENCE phase 3 trial, published in The New England Journal of Medicine, demonstrated that a greater proportion of patients with MASH achieved resolution of steatohepatitis ...

Chances are, you haven’t heard of metabolic dysfunction–associated steatohepatitis (MASH)—but you’ve almost definitely heard murmurs about GLP-1 medications like Ozempic and Wegovy. Well, the two are ...

"These data suggest that the effects of semaglutide 2.4 mg in this study may not be solely dependent on weight loss and provide important insights into the clinical effects of semaglutide 2.4 mg in ...

The survey showed that while most of the doctors didn’t have top-of-mind awareness of oral semaglutide’s upcoming FDA ...

SAN DIEGO — Semaglutide, a glucagon-like peptide 1 (GLP-1) receptor agonist, appears to safely and effectively treat metabolic dysfunction–associated steatohepatitis (MASH) among patients with ...

Novo Nordisk (NVO) announced the headline results from part 1 of the ongoing ESSENCE trial, a pivotal phase 3, 240-week, double-blinded trial in 1,200 adults with metabolic dysfunction-associated ...

Novo Nordisk announced today that Health Canada has issued marketing authorization with conditions [Notice of Compliance with ...

The MarketWatch News Department was not involved in the creation of this content. -- Secondary analyses of the ESSENCE trial were presented at the American Association for the Study of Liver Diseases ...